Common Stock, no par value
- Symbol
- CPIX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Cumberland Pharmaceuticals Inc.
CPIXNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban in this rare disease population. A copy of the release is furnished as Exhibit 99.1. Exhibit No.…
Company context
Cumberland Pharmaceuticals Inc. is a Nashville-based biopharmaceutical company focused on developing new therapies for rare diseases. The company is advancing a late-stage pipeline of product candidates through a series of late stage clinical studies. The treatments are being developed across multiple therapeutic areas to address serious patient conditions that represent unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
Current securities
Registered securities in this filing
CUMBERLAND PHARMACEUTICALS INC. · 8-K · Filed 2026-10-23
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events
On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban in this rare disease population.
A copy of the release is furnished as Exhibit 99.1.
Exhibit No. Description
─────────────────────────────────────────────────────────
99.1 Press release dated October 23, 2026